TX-MARY-KAY
24.3.2022 13:05:05 CET | Business Wire | Press release
Water is essential to life in all its forms and to the ongoing development of a healthy and sustainable future. According to the World Economic Forum , environmental risks and the impact on natural ecosystems and resources continues to be a top global risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005126/en/
This World Water Day, Mary Kay Inc. recommits to responsible and sustainable water management to ensure the ongoing availability of water as an essential resource to meet the needs of the environment and communities around the world.
Water is at the heart of Mary Kay’s sustainability strategy and crucial to its manufacturing processes. Implementing good water stewardship principles is critical for Mary Kay to reach our sustainability goals. We strive to ensure water use for human and economic needs does not disrupt sustainable water cycles or cause ongoing harm to nature and biodiversity. Recent water efforts at Mary Kay facilities include:
- Water use at U.S. Mary Kay-owned facilities decreased 36% from 2012-2017.
-
At Mary Kay’s manufacturing facility in Hangzhou, China, significant strides toward water conservation include:
- Reduced potable water use by 34%, which saves approximately 913,480 gallons of potable water per year.
- Reverse Osmosis (RO) reject water reuse: The purifying water equipment produces a large amount of concentrated water discharge in the operation process. By collecting concentrated water and passing it through the circulation system, concentrated water will be reused through the fire tower and air-cooling tower system as a supplementary water source.
- Wastewater treatment upgrade: To mitigate the environmental impact of wastewater in its manufacturing processes, Mary Kay China invested in an advanced membrane bioreactor (MBR) process using existing infrastructure to improve the capacity of wastewater treatment and reduce sludge discharge by 40%.
“As a global sustainability advocate, Mary Kay is dedicated to playing an important role in collective efforts to cause no harm to the environment and to ensure communities and economies prosper,” said Deborah Gibbins , Chief Operating Officer at Mary Kay Inc. “Mary Kay will continue to build upon its progress and work toward its commitment of reducing water utilization in our manufacturing processes by 30% by the year 2030 versus a 2020 baseline per kilogram bulk produced. Achieving Alliance for Water Stewardship (AWS) Core Certification for Mary Kay manufacturing facilities in the U.S. and China will help move us closer to our goals.”
Several key components of Mary Kay’s decade of action include:
- A current signatory of the UN Ocean Principles and CEO Water Mandate.
-
Continuing its 32-year partnership with The Nature Conservancy and supporting 11 global water projects in 2022 focusing on:
- Global ocean protection to improve ocean health for nature and people;
- Restoring Asia Pacific Shellfish Reefs in Australia, Hong Kong, China, the Coral Triangle, and the Cakaulevu Reef (also called the Great Sea Reef);
- Supporting Women Leaders in The Pacific in Papua New Guinea (Mangroves, Women, and Markets) and the Solomon Islands (Community Health and Resilience);
- Coastal Conservation and Restoration in the Gulf Coast (Protecting the Gulf Coast Coastal Wetlands);
- Improving Fisheries in Mexico (Improving Fisheries and Empowering Communities); and
- Collaborating with partners in Europe supporting native oyster restoration projects in England, Scotland, Ireland, France, the Netherlands, Germany, and Sweden.
- Joining Alliance for Water Stewardship and working to achieve certification of our two manufacturing facilities by 2025.
To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy, Enriching Lives Today for a Sustainable Tomorrow.
About Mary Kay Inc.
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn or follow us on Twitter .
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005126/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
